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esponsibility of Xi’Abstract A selective, sensitive and high-throughput liquid chromatography–tandem mass spectrometry
(LC–ESI-MS/MS) method has been developed and validated for the quantitation of Guanfacine in rat
plasma. Sample clean-up involved liquid–liquid extraction (LLE) and 100 μL of rat plasma was used.
YMC BASIC column (50 mm 2.0 mm, 3.5 mm) was used. Mobile phase used was 10 mM ammonium
formate (pH 4.0):acetonitrile (70:30, v/v) at a ﬂow rate of 0.3 mL/min. The parent-product ion
transitions for the drug (m/z 246.0-159.0) and IS (m/z 252.0-161.1) were monitored on a triple
quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) and positive ion
mode. The method was validated over the concentration range of 50.00–10,000.00 pg/mL for Guanfacine.
The method was successfully applied into a pharmacokinetic study in rat plasma.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Else
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an Jiaotong University.1. Introduction
Guanfacine is a centrally acting antihypertensive with alpha2-
adrenoceptor agonist properties in a tablet form for oral adminis-
tration. The chemical name of Guanfacine hydrochloride is
N-Amidino-2-(2,6-dichlorophenyl) acetamide monohydrochloride
(Fig. 1) and its molecular weight is 282.55 [1]. Guanfacine
principal mechanism of action appears to be stimulation of centralvier B.V. All rights reserved.
Fig. 1 Chemical structures of Guanfacine and Guanfacine 15N3
13C1.
Quantitation of Guanfacine in rat plasma by LC–ESI-MS/MS 473alpha-adrenergic receptors. By stimulating these receptors, Guan-
facine reduces sympathetic nerve impulses from the vasomotor
center to the heart and blood vessels. This results in a decrease in
peripheral vascular resistance and a reduction in heart rate.
Relative to an intravenous dose of 3 mg, the absolute oral
bioavailability of Guanfacine is about 80%. Peak plasma concen-
trations occur from 1 to 4 h with an average of 2.6 h after single
oral dose or at steady state [2]. The area under the concentration–
time curve (AUC) increases linearly with the dose. In individuals
with normal renal function, the average elimination half-life is
approximately 17 h (range 10–30 h). Younger patients tend to
have shorter elimination half-lives (13–14 h) while older patients
tend to have half-lives at the upper end of the range [3]. Steady
state blood levels were attained within 4 days in most subjects. The
drug is approximately 70% bound to plasma proteins, independent of
drug concentration. The whole body volume of distribution is high
(a mean of 6.3 L/kg), which suggests a high distribution of drug to
the tissues. Patients on dialysis also can be given usual doses of
Guanfacine as the drug is poorly dialyzed [4,5].
Nowadays, it is important to develop a most sensitive method
by using advanced instrument LC–MS/MS for clinical pharmaco-
kinetics application and bioanalysis [6–8]. Literature survey
reveals that there are few methods reported for quantitation,
identiﬁcation of Guanfacine in biological matrices [9–16], phar-
maceutical formulations [17]. These methods are developed with
different analytical instruments like HPLC–MS [12], GC–MS [14],
electron-capture gas liquid chromatography [15,16], spectropho-
tometry [17], and HPLC [18]. Among all the reported methods for
quantiﬁcation of Guanfacine in rats and human plasma, dried
blood spots methods are helpful for clinical pharmacokinetics.
The reported methods [12–18] do not show high sensitive and
rugged. It is required to develop and validate the most economical,
simple, rugged and reproducible bioanalytical method for the
quantiﬁcation of Guanfacine in biological matrices for its clinical
pharmacokinetics.
The objective of the present study is to develop a simple, sensitive,
selective, rapid, rugged and reproducible method by using LC–ESI-
MS/MS method for the quantitation of Guanfacine in rat plasma.2. Experimental
2.1. Chemicals and materials
Reference standards of Guanfacine HCl (99.7%) and Guanfacine
15N3
13C1 HCl (99.89%, IS) were procured from United States of
Pharmacopia (USP). HPLC grade methanol and acetonitrile were
obtained from Mallinckrodt Baker (S.A.de C.V. Mexico). Reagent
grade ammonium formate, sodium carbonate and formic acid were
obtained from Merck Specialties Pvt. Ltd., (Mumbai, India).
HPLC grade methyl tertiary butyl ether was obtained from RCI
Labscan (Mumbai, India). Water used in the entire analysis wasprepared from Milli-Q water puriﬁcation system procured from
Millipore (Bangalore, India). Rats and blank rat plasma were
procured from Bioneeds (Bangalore, India).
2.2. Instrumentation
The 1200 Series HPLC system (Agilent Technologies, Waldbronn,
Germany) connected to the API 4200 triple quadrupole mass
spectrometer (ABI-SCIEX, Toronto, Canada) with a turbo electro-
spray interface in a positive-ion mode was used for detection. Data
processing was performed on Analyst 1.5.1 software package (SCIEX).
2.3. Standard stock, calibration standards and quality control
sample p,reparation
The standard stock solutions of 100.00 mg/mL of Guanfacine and
Guanfacine 15N3
13C1 were prepared by dissolving requisite amount
in methanol. Calibration standards and quality control (QC) samples
were prepared with blank plasma from standard stock solution of
Guanfacine. Calibration standards were made at concentrations of
50.00, 100.00, 500.00, 1000.00, 2000.00, 4000.00, 6000.00,
8000.00 and 10,000.00 pg/mL while QC samples were prepared
at four levels, via., 7000.00 pg/mL (HQC, high quality control),
5000.00 pg/mL (MQC, middle quality control), 150.00 pg/mL
(LQC, low quality control) and 50.00 pg/mL (LLOQC, lower limit
of quality control) for Guanfacine. From internal standard stock
solution 50.00 ng/mL of IS dilution was prepared with 30% MeOH
in 0.1% formic acid and stored at 2–8 1C in the refrigerator.
Calibration standards and QC samples were stored at −30 1C
until use.
2.4. Chromatographic condition
Chromatographic separation was carried out on a reversed-phase
YMCBASIC column (50 mm 2.0 mm, 3.5 mm) using the mix-
ture of 10 mM ammonium formate buffer (pH 4) and acetonitrile
(70:30, v/v) as the mobile phase at a ﬂow rate of 0.3 mL/min at
50 1C. Retention time of Guanfacine and Guanfacine 15N3,
13C1
was found to be approximately 1.170.2 min for both the drug and
IS with a total runtime of 3.0 min.
2.5. Mass spectrometric conditions
Ionization and detection of the analyte and IS were carried out on
a triple quadrupole mass spectrometer, AB-SCIEX, (Toronto,
Canada) equipped with electrospray ionization and operated in
positive ion mode. Quantitation was performed using multiple
reaction monitoring (MRM) mode to monitor parent-product ion
(m/z) transition for Guanfacine at m/z 246.0-159.0 (Fig. 2A
and B).
For internal standard, the MH+ (m/z 252.0) was monitored as
the precursor ion (Fig. 3A) and a fragment at m/z 161.1 was
monitored as the product ion (Fig. 3B). Mass parameters were
optimized as source temperature 500 1C, nebulizer gas 30 (nitro-
gen) psi, heater gas 1 40 (nitrogen) psi, curtain gas 25 (nitrogen)
psi, CAD gas 3 (nitrogen) psi, ion spray (IS) voltage 5500 V,
source ﬂow rate 0.3 mL/min without split, entrance potential 10 V,
declustering potential 40 V for both the analyte and IS, collision
energy 16 V for both the analyte and IS, collision cell exit potential
12 V and the dwell time was set at 200 ms for the analyte and 10 V
for IS.
Fig. 2 Parent ion mass spectra (A) and product ion mass spectra (B) of Guanfacine.
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Prior to analysis, all frozen subject samples, calibration standards and
QC samples were thawed and allowed to equilibrate at room
temperature. To an aliquot of 100 μL of spiked plasma sample,
50 μL internal standard was added and vortexed brieﬂy. Further,
200 μL of 1 M sodium carbonate solution was added and vortexed
brieﬂy. To these samples, 3 mL of extraction solvent (methyl tertiary
butyl ether) was added, capped and the samples were vortexed for
15 min. Centrifugation of the samples was done at 4000g, for 5 min
at 20 1C. Supernatant from each sample was transferred into
respective tube and evaporated to dryness under nitrogen at
4072 1C. The dried samples were reconstituted with 200 μL of
acetonitrile:10 mM ammonium formate (20:80, v/v). All the tubes
containing samples were vortexed brieﬂy and transferred into
autosampler vials for injection into the chromatographic system.
2.7. Method validation
The method validation was performed as per the USFDA guide-
lines [19]. The method was validated for system suitability,
carryover, linearity, precision and accuracy, selectivity, sensitivity,
matrix effect, recovery, stability, ruggedness and dilution integrity.
2.7.1. System suitability and autosampler carryover
System suitability experiment was performed by injecting three
consecutive injections using aqueous solution of Guanfacine andinternal standard at the start of each batch during the method
validation. The carryover effect of the autosampler was evaluated
by injecting a sequence of injections solutions of aqueous
standard, mobile phase, standard blank and extracted standard
equivalent to the highest standard in the calibration range. As per
the acceptance criteria, the response in the blank should not be
greater than 20% of LOQ response.
2.7.2. Linearity and LLOQ
The linearity of the method was determined by analysis of ﬁve linear
curves containing 10 non-zero concentrations. The ratio of analyte to IS
area versus analyte concentration was used for regression analysis.
Each calibration curve was analyzed individually by using least square
weighted (1/x2) linear regression. The lowest standard on the calibration
curve was accepted as the limit of quantitation (LOQ), if the analyte
response was at least ﬁve times more than that of drug-free (blank)
extracted plasma. The deviation of standards other than LLOQ from
the nominal concentration should not be more than 715.0%. For
LLOQ it should not be more than 720.0%.
2.7.3. Precision and accuracy
For determining the intra-day accuracy and precision, replicate
analysis of plasma samples of Guanfacine was performed on the
same day. The run consisted of a calibration curve, and six
replicates of LLOQC, LQC, MQC and HQC samples. The inter-
day accuracy and precision were assessed by analysis of ﬁve
Fig. 3 Parent ion mass spectra (A) and product ion mass spectra (B) of Guanfacine 15N3
13C1.
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days. The precision of the method was determined by calculating
the percent coefﬁcient of variation (% CV) for each level. The
deviation at each concentration level from the nominal concentra-
tion was expected to be within 715.0% except LLOQ, for which
it should be within 720.0%.
2.7.4. Selectivity
The selectivity of the method towards endogenous plasma matrix
components was assessed in 10 lots (ﬁve K2 EDTA plasma lots,
two hemolyzed lots, two lipimic lots and one heparinised lot) of
blank rat plasma. This was done to estimate the extent to which
endogenous plasma components contribute towards interference at
the retention time of analytes and IS. The cross talk of MRM for
analytes and IS was checked using the highest standard on
calibration curve and working solution of IS.
2.7.5. Matrix effect
Ion suppression/enhancement effects on the MRM LC–MS/MS
sensitivity were evaluated by the post-column analyte infusion
experiment. A standard solution containing Guanfacine (at MQC
level) and IS was infused post-column into the mobile phase at
10 μL/min employing the in-built infusion pump. Aliquots of
10 μL of extracted control plasma were then injected into the
column by the autosampler and MRM LC–MS/MS chromatogram
was acquired for the analytes and IS. Any dip in the baseline uponinjection of double blank plasma (without IS) would indicate ion
suppression, while a peak at the retention time of analyte and IS
indicates ion enhancement.
2.7.6. Recovery
The relative recovery (RE) and process efﬁciency were assessed;
all three parameters were evaluated at HQC, MQC and LQC levels
in six replicates. Matrix effect was assessed at LQC and HQC
levels in six replicates.
RE was calculated by comparing the mean area response of
extracted samples (spiked before extraction) to that of un-extracted
samples (spiked after extraction) at each QC level. The recovery of IS
was similarly estimated.
The overall ‘process efﬁciency’ (% PE) was calculated as (ME
RE)/100. The assessment of relative matrix effect was based on the
direct comparison of the MS/MS responses (peak areas) of the
analytes spiked into extracts originating from different lots of
plasma. The variability in these responses, expressed as % CV
was considered as the measure of relative matrix effect.
Absolute matrix effect (ME) was assessed by comparing the
mean area response of unextracted samples (spiked after extrac-
tion) with that of neat standard solutions.
2.7.7. Stability
Stability experiments were carried out to examine the analyte
stability in stock solutions and in plasma samples under different
S.M. Goparaju et al.476conditions. Short term stability at room temperature and long-term
stability of spiked solution stored at −30 1C were assessed by
comparing the area response of stability sample of analyte and IS
with that of sample prepared from fresh stock solutions. The
solutions were considered stable if the deviation from nominal
value was within 710%.
Autosampler (wet extract) stability, bench top stability, freeze–
thaw stability and long-term stability were performed at LQC and
HQC levels using six replicates at each level. The samples were
considered stable if the deviation from the mean calculated
concentration of freshly thawed quality control samples was within
715%.2.7.8. Ruggedness
To authenticate the ruggedness of the proposed method, it was
done on two precision and accuracy batches. The ﬁrst batch was
analyzed by two different analysts while the second batch was
analyzed on a different column.2.7.9. Dilution integrity
Dilution integrity experiment was conducted by diluting the stock
solution prepared as spiked standard at concentration of 15,000.00 pg/
mL for Guanfacine. The precision and accuracy for dilution integrity
standards at 1/2 (7500.00 pg/mL) and 1/4th (3750.00 pg/mL) dilu-
tions for Guanfacine were determined by analyzing the samples
against calibration standards.2.8. Study design
The validated method has been successfully applied to quantify
Guanfacine concentrations in rat plasma. The study was conducted
according to the current GCP guidelines [20,21]. Before conduct-
ing the study it was approved by an authorized animal ethics
committee. Six healthy rats (200–400 g) were used for conducting
in-vivo studies. After an initial period of acclimatization for 1
week to laboratory conditions, the rats were randomly selected and
administered the dose. The study was designed as a single dose,
one-way cross over study with a washout period 14 days. The
protocol followed in Experimental was in accordance to Animal
Ethical Guidelines for investigations in laboratory animal and
approved by the Animal Ethics Committee (No. BION/COP/GF-
2012-6-5F), Bangalore. Animal had access to food 2 h after dose
administration. There were a total of 13 blood collection time
points including the predose sample (0, 0.5, 1.5, 3, 4, 8, 14, 20, 32,
44, 56, 68, 92 h). The blood samples were collected in separate
vacutainers containing K2EDTA as an anticoagulant. The plasma
from these samples was separated by centrifugation at 4000 rpm
within the range of 2–8 1C. The plasma samples thus obtained
were stored at −30 1C until analysis. After analysis the pharma-
cokinetic parameters were computed using WinNonlins software
version 5.2.3. Results and discussion
3.1. Method development
During method development, different options were evaluated to
optimize mass spectrometry detection parameters, chromatography
and sample extraction.3.1.1. Mass spectrometry detection parameters optimization
Electrospray ionization (ESI) provided a maximum response over
atmospheric pressure chemical ionization (APCI) mode, and was
chosen for this method. The instrument was optimized to obtain
sensitivity and signal stability during infusion of the analyte in the
continuous ﬂow of mobile phase to electrospray ion source
operated at both polarities at a ﬂow rate of 20 μL/min. Guanfacine
gave more responses in positive ion mode as compared to the
negative ion mode. The collisionally activated dissociation (CAD)
mass spectrum of Guanfacine shows formation of characteristic
product ions at m/z 159.0. The major product ion at m/z 159.0 for
Guanfacine could be from the protonated precursor molecule. The
CAD mass spectrum of Guanfacine 15N3
13C1 shows formation of
characteristic product ions at m/z 159.1, 161.1, 162.0 and 163.0.
The major product ion at m/z 161.1 arose from the protonated
precursor molecule. The predominant peaks in the primary ESI
spectra of Guanfacine and Guanfacine 15N3
13C1 correspond to the
[M+H]+ ions at m/z 246.0 and 252.0 respectively. (Figs. 2A and
3A). Product ions of Guanfacine and Guanfacine 15N3
13C1 were
m/z of 159.0 and 161.1 respectively (Figs. 2B and 3B).3.1.2. Chromatography optimization
Initially, a mobile phase consisting of ammonium formate and
methanol in varying combinations was tried, but a low response
was observed. The mobile phase containing ammonium acetate:
acetonitrile (20:80, v/v) gave a better response, but poor peak
shape was observed. A mobile phase with various strengths of
ammonium formate in water at pH 4 in combination with methanol
and acetonitrile with varying combinations was tried. Using a
mobile phase containing ammonium formate (pH 4) in water in
combination with acetonitrile (70:30, v/v), the best signal along
with a marked improvement in the peak shape was observed for
Guanfacine and Guanfacine 15N3
13C1.
Short length columns, such as Symmetry Shield RP18
(50 mm 2.1 mm, 3.5 μm), Inertsil ODS-2V (50 mm 4.6 mm,
5 μm), Hypurity C18 (50 mm 4.6 mm, 5 μm) and Hypurity
Advance (50 mm 4.0 mm2, 5 μm) were tried during the method
development. Symmetry Shield RP18 column gave a relatively
good peak shape, but the response was low. Using Hypurity C18
column poor chromatography was observed. The best signal was
obtained using the YMC BASIC (50 mm 2.0 mm, 3.5 mm)
column. It gave satisfactory peak shapes for both Guanfacine
and Guanfacine 15N3
13C1. Flow rate of the mobile phase was
adjusted and optimized at 0.3 mL/min without splitter. Both the
drug and IS were eluted at 1.1 min with the total run time of 3 min.
For an LC–MS/MS analysis, utilization of stable isotope-labeled or
suitable analog drugs as an internal standard proves helpful when a
signiﬁcant matrix effect is possible. In our case, Guanfacine 15N3
13C1 was found to be the best for the present purpose. The column
oven temperature was kept at a constant temperature of about
50 1C. Injection volume of 20 mL sample was adjusted for better
ionization and chromatography.3.1.3. Extraction optimization
Prior to load the sample for LC injection, the co-extracted proteins
should be removed from the prepared solution. For this purpose,
initially we tested with different extraction procedures like protein
precipitation (PP), liquid–liquid extraction (LLE), and solid phase
extraction (SPE). We found ion suppression effect in PP method
for drug and internal standard. Further, we tried with SPE and
LLE. Among all we found that LLE is suitable for extraction of
Quantitation of Guanfacine in rat plasma by LC–ESI-MS/MS 477drug and IS. We tried with several organic solvents (ethyl acetate,
chloroform, n-hexane, dichloromethane and methyl tertiary butyl
ether) individually as well with combinations in LLE to extract
analyte from the plasma sample. In our case methyl tertiary butyl
ether:dichloromethane (80:20) combination served as a good
extraction solvent. Auto sampler wash is optimized as 50% acetoni-
trile in 0.1% formic acid. High recovery and selectivity were observed
in the LLE method. These optimized detection parameters, chromato-
graphic conditions and extraction procedure resulted in reduced
analysis time with accurate and precise detection of Guanfacine in
rat plasma.3.2. Method validation
The method was validated in terms of system suitability, carryover,
linearity, selectivity, precision and accuracy, sensitivity, matrix effect,
recovery, stability, ruggedness and dilution integrity [19].3.2.1. System suitability and autosampler carryover
Throughout the method validation, the %CV of the system
suitability was observed below 5.0% at the retention time of
Guanfacine and the IS. Carryover evaluation was performed in
each analytical run to ensure that it does not affect the accuracy
and the precision of the proposed method. There was a negligible
carryover (≤5% of the LLOQ response) observed during auto-
sampler carryover experiment. No enhancement in the response
was observed in double blank after subsequent injection of the
highest calibration standard (aqueous and extracted) at the reten-
tion time of analyte and IS.Fig. 4 LLOQ chromatogram of Guanfacine (A)3.2.2. Linearity
The calibration curves were linear over the concentration range of
50.00–10,000.00 pg/mL with the correlation coefﬁcient r≥0.9850
for Guanfacine Fig. 4 (Table 1).
3.2.3. Precision and accuracy
The accuracy and precision (% CV) observed for the calibration
standards ranged from 96.84% to 102.40% and 0.41% to 1.94%
for Guanfacine respectively. The lowest concentration (LLOQ) in
the standard curve for Guanfacine was measured at a signal-to-
noise ratio (S/N) of ≥20. The intra- and inter-batch precision and
accuracy were established from validation runs performed at HQC,
MQC, LQC and LLOQ QC levels. The intra- and inter-batch
precision ranged from 0.93% to 3.24% and 1.50% to 3.38%
respectively for Guanfacine. The accuracy values were within
97.89–102.76% and 97.98–101.39% for the analyte in intra- and
inter-batches (Table 2).
3.2.4. Selectivity
To establish the selectivity of the method for interference due to
endogenous plasma components from haemolysed, lipidemic,
heparinised and K2EDTA blank plasmas, the % change in the
area ratio (analyte/IS) at LLOQ level was within 4–6%, while the
precision (% CV) in their measurement varied from 2.0 to 4.5.
The extraction procedure together with mass detection gave a
very good selectivity for the analysis of drug and IS in the blank
plasma. No endogenous interferences were found at the retention
times of analyte and IS.
3.2.5. Matrix effect
Matrix effect may be deﬁned as a composite of some undesirable
effects that originate from a biological matrix. These components
may result in ion suppression/enhancement, decrease/increase inand Guanfacine 15N3
13C1 (B) in rat plasma.
S.M. Goparaju et al.478sensitivity of analytes over a period of time, increased baseline,
imprecision of data, drift in retention time and distortion or tailing
of a chromatographic output. Result of post-column infusion
experiment indicates no ion suppression or enhancement at the
retention time of analyte and IS as evident from the ﬂat baseline.
There is no ion suppression and enhancement observed at retention
time of analyte and IS.
3.2.6. Recovery
The relative recovery and process efﬁciency for drug were observed
as 79.96%. The recovery for IS in rat plasma was 87.50%.
3.2.7. Stability
Stock solution stability was performed to check stability of
Guanfacine and Guanfacine 15N3
13C1 in stock solutions prepared
in methanol and stored at 2–8 1C in a refrigerator. The freshly
prepared stock solutions were compared with stock solutions
prepared before 9 days. The % change for Guanfacine and
Guanfacine 15N3
13C1 were less than 5% which indicated that
stock solutions were stable at least for 9 days.
Bench top and autosampler stability for Guanfacine was
investigated at LQC and HQC levels. The results revealed that
Guanfacine was stable in plasma for at least 26 h at room
temperature, and 46 h in an auto sampler. It was conﬁrmed that
repeated freezing and thawing (three cycles) of plasma samples
spiked with Guanfacine at LQC and HQC levels did not affect
their stability. The long-term stability results also indicated that
Guanfacine was stable in a matrix up to 65 days at a storage
temperature of −30 1C. The results obtained from all these stability
studies are tabulated in Table 3.
3.2.8. Ruggedness
The results of ruggedness study for Guanfacine were well within
the acceptance limit of 15% in precision and 85.0–115.0% in meanTable 1 Calibration curve details.
Concentration (pg/mL) Mean7S.D.
50.00 50.5470.44
100.00 98.1071.90
500.00 484.2076.38
1000.00 1024.00715.17
2000.00 2022.0078.37
4000.00 3998.00720.49
6000.00 6032.00742.07
8000.00 8036.00757.71
10,000.00 9960.00756.57
S.D. Standard deviation; CV¼Coefﬁcient of variation.
Table 2 Intra-batch and inter-batch precision and accuracy.
Nominal added concentration (pg/mL) Intra-batch(n¼6)
Mean7S.D. Precision (% CV
50.0 50.7571.06 2.08
150.0 146.8374.75 3.24
5000.0 5021.67746.65 0.93
7000.0 7193.33783.35 1.16
S.D: Standard deviation, CV¼coefﬁcient of variation.accuracy. The precision and accuracy values for both experiments
at LLOQ, LQC, MQC and HQC levels for Guanfacine ranged
from 1.6% to 4.9% and 98.40% to 107.21% respectively.
3.2.9. Dilution integrity
The dilution integrity experiment was performed with an aim to
validate the dilution test to be carried out on higher analyte
concentration above the upper limit of quantiﬁcation (ULOQ),
which may be encountered during real subject sample analysis.
The precision and accuracy values for 1/2th and 1/4th dilution
ranged from 4.9% to 5.2% and 102.8% to 103.8% for Guanfacine.3.3. Application of the method
The validated method has been successfully applied to quantify
Guanfacine concentrations into a single dose (72 mg/200 g) in rats.
Male Sprague-Dawley rats were obtained from Bioneeds, Banga-
lore. After i.v. administration of drug via left femoral vein 0.2 mL
of blood samples for analytical determinations was collected via
the right femoral vein at speciﬁc time intervals for 92 h. Plasma
samples were stored at −30 1C until analysis. The study was
carried out after the approval from an independent animal ethics
committee. The pharmacokinetic parameters evaluated were max-
imum observed drug concentration during the study (Cmax), area
under the plasma concentration–time curve measured 92 h, using
the trapezoidal rule (AUC0–92), time to reach maximum drug
concentration (Tmax), apparent ﬁrst order terminal rate constant
calculated from a semi-log plot of the plasma concentration versus
time curve, using the method of least square regression (Kel) and
terminal half-life as determined by quotient 0.693/Kel (T1/2) [21].
Both compartmental and a noncompartmental methods were used
for analysis of kinetic parameters. Pharmacokinetic details are
shown in Table 4. The mean concentration versus time proﬁle of
Guanfacine in rat plasma is shown in Fig. 5.%CV Accuracy (%)
0.88 101.08
1.94 98.10
1.32 96.84
1.48 102.40
0.41 101.10
0.51 99.95
0.70 100.53
0.72 100.45
0.57 99.60
Inter-batch(n¼36)
) Accuracy (%) Mean7S.D. Precision (% CV) Accuracy (%)
101.50 50.6771.71 3.38 101.35
97.89 146.9773.65 2.49 97.98
100.43 4978.33774.79 1.50 99.57
102.76 7097.337126.43 1.78 101.39
Table 3 Stability of Guanfacine in rat plasma samples.
Stability Spiked plasma concentration
(pg/mL)
Concentration measured
(pg/mL) (mean7S.D.; n¼6)
CV (%) (n¼6)
Bench-top stability (26 h) 150.00 143.1771.83 1.28
7000.00 6931.67773.33 1.06
Autosampler stability (46 h) 150.00 144.0072.45 1.70
7000.00 7030.00740.00 0.57
Long term stability (65 days) 150.00 140.1777.57 5.40
7000.00 7013.337508.67 7.25
Freeze and thaw stability (Cycle 3, 48 h) 150.00 148.6772.16 1.45
7000.00 7038.33768.53 0.97
Table 4 Mean pharmacokinetic parameters of Guanfacine in
rat plasma after intravenous administration of 72 mg/200 g
male rat.
Pharmacokinetic parameter Values
AUC0–t (pg h/mL) 10,155789
Cmax (pg/mL) 3275752
AUC0–∞ (pg h/mL) 103,113792
Kel (h1) 0.04870
Tmax (h) 0.5
t1/2 (h) 14.23
AUC0–∞: area under the curve extrapolated to inﬁnity; AUC0–t:
area under the curve up to the last sampling time; Cmax: the
maximum plasma concentration; Tmax: the time to reach peak
concentration; Kel: the apparent elimination rate constant.
Fig. 5 Mean plasma concentrations versus time graph of Guanfacine
after intravenous administration of 72 mg/200 g in male rat.
Quantitation of Guanfacine in rat plasma by LC–ESI-MS/MS 4794. Conclusion
The proposed method exhibited excellent performance in terms of
sensitivity, selectivity, ruggedness and efﬁciency (3.0 min/sample)
due to cleaner extracts, with simplicity of sample preparation. This
method was successfully applied in pharmacokinetics of rat plasma.Acknowledgments
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